PT1583830E - Método para produzir proteínas policlonais recombinantes - Google Patents

Método para produzir proteínas policlonais recombinantes Download PDF

Info

Publication number
PT1583830E
PT1583830E PT04700438T PT04700438T PT1583830E PT 1583830 E PT1583830 E PT 1583830E PT 04700438 T PT04700438 T PT 04700438T PT 04700438 T PT04700438 T PT 04700438T PT 1583830 E PT1583830 E PT 1583830E
Authority
PT
Portugal
Prior art keywords
cells
polyclonal
nucleic acid
cell
protein
Prior art date
Application number
PT04700438T
Other languages
English (en)
Portuguese (pt)
Inventor
Jacqueline Sharon
John S Haurum
Finn C Wiberg
Vincent W Coljee
Chiou-Ying Yang
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of PT1583830E publication Critical patent/PT1583830E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
PT04700438T 2003-01-07 2004-01-07 Método para produzir proteínas policlonais recombinantes PT1583830E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43840303P 2003-01-07 2003-01-07
DKPA200300008 2003-01-07
US47601803P 2003-06-05 2003-06-05

Publications (1)

Publication Number Publication Date
PT1583830E true PT1583830E (pt) 2006-11-30

Family

ID=32718469

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04700438T PT1583830E (pt) 2003-01-07 2004-01-07 Método para produzir proteínas policlonais recombinantes

Country Status (18)

Country Link
US (1) US9163232B2 (enExample)
EP (2) EP1762617A1 (enExample)
JP (2) JP4589914B2 (enExample)
KR (1) KR101024443B1 (enExample)
AT (1) ATE338816T1 (enExample)
AU (1) AU2004203727C1 (enExample)
BR (1) BRPI0406678A (enExample)
CA (1) CA2512647C (enExample)
DE (1) DE602004002275T2 (enExample)
DK (1) DK1583830T3 (enExample)
EA (1) EA013225B1 (enExample)
ES (1) ES2273202T3 (enExample)
IL (1) IL169101A (enExample)
MX (1) MXPA05006724A (enExample)
NZ (1) NZ541458A (enExample)
PT (1) PT1583830E (enExample)
SI (1) SI1583830T1 (enExample)
WO (1) WO2004061104A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
RU2426795C2 (ru) 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
US8815583B2 (en) 2005-06-24 2014-08-26 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
MX2009008908A (es) 2007-03-01 2009-08-28 Symphogen As Metodo para clonacion de anticuerpos analogos.
PL2132229T3 (pl) 2007-03-01 2016-12-30 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka
CN101679513A (zh) 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
NZ581316A (en) * 2007-05-25 2012-02-24 Symphogen As Method for manufacturing a recombinant polyclonal protein
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
HUE025262T2 (en) 2007-10-11 2016-02-29 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-linked Siglec-15 protein
BRPI0910454A2 (pt) * 2008-04-23 2018-03-27 Symphogen As processo para produção de uma proteína policlonal
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
CN106317224B (zh) 2009-04-09 2020-05-12 第一三共株式会社 抗-Siglec-15抗体
NZ599315A (en) 2009-10-15 2014-05-30 Avaxia Biologics Inc Antibody therapeutics with local activity in the digestive tract
CN103282495B (zh) 2010-10-29 2017-06-09 第一三共株式会社 新的抗dr5抗体
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
CA2817751C (en) 2010-11-16 2019-04-30 Excelimmune, Inc. Methods for producing recombinant proteins
LT2703486T (lt) 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
EP3816284A1 (en) 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expression vector for antibody production in eukaryotic cells
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
AU2013241002A1 (en) 2012-03-30 2014-10-09 Daiichi Sankyo Company,Limited Novel anti-siglec-15 antibody
KR20150003170A (ko) 2012-03-30 2015-01-08 다이이찌 산쿄 가부시키가이샤 ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체
CA2870126C (en) 2012-04-09 2020-10-27 Daiichi Sankyo Company, Limited Anti-fgfr2 antibody
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
MX356749B (es) 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
WO2013164689A2 (en) 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
JP2015163047A (ja) * 2012-06-20 2015-09-10 国立大学法人 東京大学 タンパク質の迅速改良法
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
EP3061818B1 (en) 2013-09-30 2020-12-16 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
ES2768618T3 (es) 2013-10-08 2020-06-23 Daiichi Sankyo Co Ltd Combinación de anticuerpo anti-FGFR2 y otro agente
WO2015093925A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Isaac Método de producción de anticuerpos específicos
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
SI3110849T1 (sl) 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
EP3345928B1 (en) 2015-07-10 2020-06-24 Merus N.V. Human cd3 binding antibody
JP7054924B2 (ja) 2015-09-23 2022-04-15 サイトイミューン セラピューティクス， インコーポレイテッド 免疫療法のためのｆｌｔ３指向ｃａｒ細胞
JP6878283B2 (ja) 2015-09-24 2021-05-26 第一三共株式会社 抗ｇａｒｐ抗体
BR112018008068A2 (en) 2015-10-23 2018-11-13 Merus N.V. binding molecules that inhibit cancer growth
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
EP4606383A3 (en) 2016-12-22 2025-12-17 Daiichi Sankyo Company, Limited Anti-cd3 antibody and molecules comprising the antibody
SG11201907321TA (en) 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
CA3058343A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
CN110621698B (zh) 2017-04-05 2024-04-12 法国施维雅药厂 靶向pd-1、tim-3及lag-3的组合疗法
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
JP7271424B2 (ja) 2017-07-27 2023-05-11 第一三共株式会社 抗ｃｄ１４７抗体
HUE071182T2 (hu) 2017-08-09 2025-08-28 Merus Nv EGFR és CMET kötõ antitestek
CN111447952A (zh) 2017-10-05 2020-07-24 第一三共株式会社 用于细胞毒性t细胞耗竭的组合物
AU2018383600B2 (en) 2017-12-11 2025-10-02 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
JP6790307B2 (ja) 2018-05-31 2020-11-25 第一三共株式会社 抗ヒトｔｌｒ７抗体
MA52945A (fr) 2018-06-22 2021-04-28 Genmab As Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
CN112673023B (zh) 2018-07-10 2023-09-12 国立大学法人神户大学 抗SIRPα抗体
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
SG11202103334YA (en) * 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
WO2021020282A1 (ja) 2019-07-26 2021-02-04 学校法人埼玉医科大学 Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
WO2021079958A1 (ja) 2019-10-25 2021-04-29 第一三共株式会社 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
WO2021136835A1 (en) 2019-12-31 2021-07-08 Antagonis Compositions and methods for the prevention of s. aureus infection
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
US11975066B2 (en) 2020-08-31 2024-05-07 SAB Biotherapeutics, Inc. Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
WO2024240634A1 (en) 2023-05-19 2024-11-28 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155114A (en) * 1874-09-15 Improvement in methods of laying and forming cast-iron pipes
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
WO1991016074A1 (en) 1990-04-19 1991-10-31 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
DK1231268T3 (da) * 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
CA2283740C (en) * 1997-03-14 2006-06-27 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
US6632672B2 (en) * 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US20020155114A1 (en) 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2001005961A1 (en) 1999-07-14 2001-01-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
DK1234022T3 (da) 1999-07-23 2010-07-19 Univ California DNA-rekombination i eukaryote celler med bakteriofag PHIC31-rekombinationssystemet
EP1283720B1 (en) * 2000-05-26 2007-04-18 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
WO2001094571A1 (fr) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Vecteur d'expression permettant le criblage de cellules a haute expression de proteine de recombinaison, transformant a haute expression de proteine de recombinaison, et leur utilisation
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
EP1337631A2 (en) * 2000-11-28 2003-08-27 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
US20030044398A1 (en) 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
AR047440A1 (es) 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
RU2426795C2 (ru) 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
KR20080113223A (ko) 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
NZ581316A (en) 2007-05-25 2012-02-24 Symphogen As Method for manufacturing a recombinant polyclonal protein

Also Published As

Publication number Publication date
HK1078896A1 (en) 2006-03-24
US9163232B2 (en) 2015-10-20
BRPI0406678A (pt) 2005-12-20
MXPA05006724A (es) 2005-09-08
DE602004002275D1 (de) 2006-10-19
EA200501101A1 (ru) 2006-02-24
DK1583830T3 (da) 2007-01-15
US20090136498A1 (en) 2009-05-28
JP2010268806A (ja) 2010-12-02
CA2512647A1 (en) 2004-07-22
KR101024443B1 (ko) 2011-03-23
EA013225B1 (ru) 2010-04-30
AU2004203727C1 (en) 2008-08-21
SI1583830T1 (sl) 2006-12-31
JP4589914B2 (ja) 2010-12-01
ES2273202T3 (es) 2007-05-01
ATE338816T1 (de) 2006-09-15
AU2004203727A1 (en) 2004-07-22
AU2004203727B2 (en) 2008-01-31
DE602004002275T2 (de) 2007-09-06
EP1583830A2 (en) 2005-10-12
JP2006515520A (ja) 2006-06-01
EP1762617A1 (en) 2007-03-14
NZ541458A (en) 2006-04-28
CA2512647C (en) 2013-10-08
WO2004061104A2 (en) 2004-07-22
IL169101A (en) 2009-02-11
KR20050101538A (ko) 2005-10-24
EP1583830B1 (en) 2006-09-06
WO2004061104A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
PT1583830E (pt) Método para produzir proteínas policlonais recombinantes
EP2152872B1 (en) Method for manufacturing a recombinant polyclonal protein
US8198415B2 (en) Anti-rhesus D recombinant polyclonal antibody
US20110117605A1 (en) Methods for Manufacturing a Polyclonal Protein
US20060275766A1 (en) Method for manufacturing recombinant polyclonal proteins
CN100383244C (zh) 用于生产重组多克隆蛋白质的方法
AU2008201796A1 (en) Method for manufacturing recombinant polyclonal proteins
HK1078896B (en) Method for manufacturing recombinant polyclonal proteins
ES2350385T3 (es) Procedimiento de fabricación de una proteína policlonal recombinante.
HK1134519B (en) Method for manufacturing a recombinant polyclonal protein